Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Location Directory

Clinical trials in Jacksonville, Florida

This page shows live ClinicalTrials.gov search results for Jacksonville, Florida, with direct links to official study records plus on-page filtering and sorting for broad location searches.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 10:15 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
7630
Shown on this page
12
Current sort
Recently updated
Location scope
Jacksonville, FL
Filters apply within this location only.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this location

These controls apply only within Jacksonville, Florida. Default order is Recently updated. Use recruitment status if you want to focus on actively recruiting studies in this location.

Reset location filters
Clear filters
Showing 481–492 of 7,630 matching trials in Jacksonville, FL.
Live ClinicalTrials.gov results.
Local directory summary panels are hidden while filters are applied so the page stays focused on the filtered live results.

Institutions in Jacksonville

Campus pages list official records that name the campus as a study site. Listed in directory order, not ranked.

Live official records

Open in full search
Active, not recruiting Phase 2 Interventional

Testing the Role of FDG-PET/CT to Predict Response to Therapy Prior to Surgery for HER2-positive Breast Cancer, The DIRECT Trial

NCT05710328
View directory record Official record
Conditions
Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, HER2-Positive Breast Carcinoma, Invasive Breast Carcinoma
Interventions
Chemotherapy, Computed Tomography, Fludeoxyglucose F-18, Positron Emission Tomography, Surgical Procedure
Drug · Procedure · Other
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
18 Years and older
Enrollment
235 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
97
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 81 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Nov 5, 2026, 10:15 AM EST
Recruiting Phase 3 Interventional

SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)

NCT05303519
View directory record Official record
Conditions
Glioma, Astrocytoma, Grade IV, IDH1-mutant Glioma, Astrocytoma, IDH-Mutant, Grade 3, Astrocytoma, IDH-Mutant, Grade 4, Astrocytoma, IDH-Mutant, Grade 2, Oligodendroglioma, Oligodendroglioma, IDH-Mutant and 1p/19q-Codeleted
Interventions
safusidenib, Placebo
Drug
Lead sponsor
Nuvation Bio Inc.
Industry
Eligibility
18 Years and older
Enrollment
365 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
46
States / cities
Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 38 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Nov 5, 2026, 10:15 AM EST
Active, not recruiting Phase 2 Interventional

Study of Chemotherapy, With or Without Binimetinib in Advanced Biliary Tract Cancers in 2nd Line Setting (A ComboMATCH Treatment Trial)

NCT05564403
View directory record Official record
Conditions
Advanced Biliary Tract Carcinoma, Advanced Gallbladder Carcinoma, Advanced Intrahepatic Cholangiocarcinoma, Recurrent Biliary Tract Carcinoma, Recurrent Gallbladder Carcinoma, Recurrent Intrahepatic Cholangiocarcinoma, Stage III Distal Bile Duct Cancer AJCC v8, Stage III Gallbladder Cancer AJCC v8, Stage III Hilar Cholangiocarcinoma AJCC v8, Stage III Intrahepatic Cholangiocarcinoma AJCC v8, Stage IV Distal Bile Duct Cancer AJCC v8, Stage IV Gallbladder Cancer AJCC v8, Stage IV Hilar Cholangiocarcinoma AJCC v8, Stage IV Intrahepatic Cholangiocarcinoma AJCC v8, Unresectable Biliary Tract Carcinoma, Unresectable Gallbladder Carcinoma, Unresectable Intrahepatic Cholangiocarcinoma
Interventions
Binimetinib, Biopsy Procedure, Biospecimen Collection, Bone Scan, Computed Tomography, Echocardiography Test, Fluorouracil, Leucovorin Calcium, Magnetic Resonance Imaging, Multigated Acquisition Scan, Oxaliplatin
Drug · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
207
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 162 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Nov 5, 2026, 10:15 AM EST
Recruiting Not applicable Interventional

Effect of Neuro20 Functional Electrical Stimulation Suit on Autonomic Function, Muscle Performance, and Gait

NCT07164846
View directory record Official record
Conditions
Spinal Cord Injury, Stroke, Amputees
Interventions
Therapy Sessions
Device
Lead sponsor
Brooks Rehabilitation
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
2
States / cities
Jacksonville, Florida • Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Nov 5, 2026, 10:15 AM EST
Active, not recruiting Phase 2 Interventional

CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapy

NCT04266249
View directory record Official record
Conditions
Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Invasive Breast Carcinoma, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8
Interventions
Docetaxel, Lumpectomy, Mastectomy, Nab-paclitaxel, Paclitaxel, Pertuzumab, Radiation Therapy, Trastuzumab, Trastuzumab Emtansine
Drug · Procedure · Biological + 1 more
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
18 Years and older
Enrollment
2,175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2038
U.S. locations
999
States / cities
Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 674 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Nov 5, 2026, 10:15 AM EST
Active, not recruiting Phase 2 Interventional

Finding an Effective Dose of GM1 to Reduce or Prevent Neuropathy (Numbness or Weakness) Due to Treatment With Paclitaxel

NCT05751668
View directory record Official record
Conditions
Anatomic Stage IV Breast Cancer AJCC v8, Chemotherapy-Induced Peripheral Neuropathy, Metastatic Breast Carcinoma
Interventions
Paclitaxel, Monosialotetrahexosylganglioside, Questionnaire Administration, Quality-of-life assessment, Placebo Administration
Drug · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
33
States / cities
Irvine, California • Orange, California • Clearwater, Florida + 26 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Nov 5, 2026, 10:15 AM EST
Active, not recruiting No phase listed Observational

Predicting Responsiveness in Oncology Patients Based on Host Response Evaluation During Anti Cancer Treatments

NCT04056247
View directory record Official record
Conditions
Stage IV Non-small Cell Lung Cancer, Stage IV Malignant Melanoma, Stage IV Small Cell Lung Cancer, Stage III Unresectable Non-Small Cell Lung Cancer, Stage IIIb-d Malignant Melanoma
Interventions
Plasma sample collection
Other
Lead sponsor
OncoHost Ltd.
Industry
Eligibility
18 Years and older
Enrollment
10,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2029
U.S. locations
12
States / cities
Birmingham, Alabama • Jacksonville, Florida • Miami, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Nov 5, 2026, 10:15 AM EST
Recruiting Phase 3 Interventional

Using 18F-FAPI PET to Detect Metastatic Disease in Patients That Have Pancreatic Ductal Adenocarcinoma (PDAC)

NCT07217717
View directory record Official record
Conditions
Pancreatic Ductal Adenocarcinoma (PDAC)
Interventions
[18F]FAPI-74 PET/CT
Drug
Lead sponsor
SOFIE
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
19
States / cities
Cerritos, California • Duarte, California • Irvine, California + 15 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Nov 5, 2026, 10:15 AM EST
Recruiting Phase 1 Interventional

Evaluation of the Tolerability of Cagrilintide in Participants Not Tolerating GLP-1-RA Therapies Due to Gastrointestinal Adverse Events

NCT07607587
View directory record Official record
Conditions
Obesity, Overweight
Interventions
Cagrilintide, Placebo (matched to Cagrilintide)
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
13
States / cities
Walnut Creek, California • Fleming Island, Florida • Jacksonville, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Nov 5, 2026, 10:15 AM EST
Enrolling by invitation Phase 3 Interventional

A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Active Idiopathic Inflammatory Myopathy

NCT05979441
View directory record Official record
Conditions
Myositis, Active Idiopathic Inflammatory Myopathy, Dermatomyositis, Polymyositis, Immune-Mediated Necrotizing Myopathy, Antisynthetase Syndrome
Interventions
Efgartigimod PH20 SC
Biological
Lead sponsor
argenx
Industry
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
18
States / cities
Phoenix, Arizona • Beverly Hills, California • Orange, California + 15 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Nov 5, 2026, 10:15 AM EST
Active, not recruiting Phase 3 Interventional

A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab

NCT06389136
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Upadacitinib 15mg Dose, Dupilumab 300mg Dose, Upadacitinib 30mg Dose
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 63 Years
Enrollment
184 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
84
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Fayetteville, Arkansas + 70 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Nov 5, 2026, 10:15 AM EST
Recruiting Not applicable Interventional

Evaluating the Efficacy of a "Quiet Knee Protocol" in Primary Total Knee Arthroplasty (TKA): A Prospective Randomized Study

NCT07879014
View directory record Official record
Conditions
Rehabilitation Exercise
Interventions
Quiet Knee Protocol, Post Operative Standard of Care
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 100 Years
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
2
States / cities
Jacksonville, Florida • New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Nov 5, 2026, 10:15 AM EST